Echinocandin pharmacodynamics: Review and clinical implications

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 6, 2010, Pages 1108-1118

  Pound, Melanie W ^a   Townsend, Mary L ^a   Drew, Richard H ^a,b  

^a Campbell University   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anidulafungin; Caspofungin; Micafungin

Indexed keywords

AMINOCANDIN; AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CLAVISPORA LUSITANIAE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MEGADOSE; ESOPHAGUS CANDIDIASIS; FUNGICIDAL ACTIVITY; FUSARIOSIS; FUSARIUM SOLANI; HUMAN; INVASIVE CANDIDIASIS; KLUYVEROMYCES MARXIANUS; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG ASPERGILLOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MUCOCUTANEOUS CANDIDIASIS; MUCORMYCOSIS; NEUTROPENIA; NONHUMAN; OROPHARYNX CANDIDIASIS; PHARMACODYNAMICS; PICHIA GUILLIERMONDII; RHIZOPUS ORYZAE; SINGLE DRUG DOSE; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; DISEASE MODELS, ANIMAL; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; TREATMENT OUTCOME;

EID: 77953504211     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq081     Document Type: Article

References (140)

1. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
2. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
3. Wagner C, Graninger W, Presterl E et al. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006; 78: 161-77.
4. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm 2006; 63: 1813-20.
5. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, Part 1. Am J Health Syst Pharm 2006; 63: 1693-703.
6. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-49.
7. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888-97.
8. Singh N, Limaye AP, Forrest G et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320-6.
9. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
10. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
11. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
12. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
13. Di Bonaventura G, Spedicato I, Picciani C et al. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob Agents Chemother 2004; 48:4453-6.
14. Ernst EJ, Klepser ME, Ernst ME et al. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 1999; 33: 75-80.
15. Venisse N, Gregoire N, Marliat M et al. Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans. Antimicrob Agents Chemother 2008; 52: 937-43.
16. Cota J, Carden M, Graybill JR et al. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother 2006; 50: 3926-8.
17. Ernst EJ, Roling EE, Petzold CR et al. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002; 46: 3846-3853.
18. Nguyen KT, Ta P, Hoang BT et al. Anidulafungin is fungicidal and exerts a variety of post-antifungal effects against Candida albicans, C. glabrata, C. parapsilosis and C. krusei isolates. Antimicrob Agents Chemother 2009; 53: 3347-52.
19. Andes D, Marchillo K, Lowther J et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 1187-92.
20. Chamilos G, Lewis RE, Albert N et al. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 2007; 51: 2257-9.
21. Fleischhacker M, Radecke C, Schulz B et al. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis 2008; 27: 127-31.
22. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008; 46:2620-9.
23. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
24. Kartsonis N, Killar J, Mixson L et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005; 49: 3616-23.
25. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27: 369-88.
26. Louie A, Deziel M, Liu W et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49: 5058-68.
27. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006; 50: 2522-4.
28. Hernandez S, Lopez-Ribot JL, Najvar LK et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004; 48: 1382-3.
29. Kahn JN, Garcia-Effron G, Hsu MJ et al. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007; 51: 1876-8.
30. Krogh-Madsen M, Arendrup MC, Heslet L et al. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42: 938-44.
31. Laverdiere M, Lalonde RG, Baril JG et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57: 705-8.
32. Prabhu RM, Orenstein R. Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis. Clin Infect Dis 2004; 39: 1253-4.
33. Miller CD, Lomaestro BW, Park S et al. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 2006; 26: 877-80.
34. Moudgal V, Little T, Boikov D et al. Multiechinocandinand multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49: 767-9.
35. Pelletier R, Alarie I, Lagace R et al. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol 2005; 43: 559-64.
36. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-30.
37. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150-6.
38. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44: 1108-11.
39. Caspofungin. Micromedex. http://www.thomsonhc.com/hcs/librarian/PFActionId/hcs.external.RetrieveDocument/eid/539870001/DocUd/2516/ContentSetCode/DRUGDEX-EVALS#pharmacokineticsSection (11 November 2009, date last accessed).
40. Anidulafungin. Micromedex. http://www.thomsonhc.com/hcs/libraian/PFActionId/hcs.external.RetrieveDocument/eid/539870001/DocId/2292/ContentSetCode/DRUGDEX-EVALS#pharmacokineticsSection (11 November 2009, date last accessed).
41. Micafungin. Micromedex. http://www.thomsonhc.com/hcs/librarian/PFActionId/hcs.external.RetrieveDocument/eid/539870001/DocId/2296/ContentSetCode/DRUGDEX-EVALS#pharmacokineticsSection (11 November 2009, date last accessed).
42. Gumbo T, Drusano GL, Liu W et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007; 51: 968-74.
43. Andes DR, Diekema DJ, Pfaller MA et al. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008; 52: 3497-503.
44. Andes D, Marchillo K, Bohrmueller J. In vivo pharmacodynamic characterization of a new echinocandin, micafungin (M), against Candida albicans and Candida glabrata in the neutropenic murine disseminated candidiasis model. In: Abstracts of the Forty-eighth Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/Forty-sixth Annual Infectious Diseases Society of America, Washington, DC, 2008. Abstract A-009, p. 3. American Society for Microbiology, Washington, DC, USA.
45. Petraitis V, Petraitiene R, Groll AH et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857-69.
46. Warn P, Sharp A, Morrissey G et al. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother 2002; 50: 1071-4.
47. Andes D, Diekema DJ, Pfaller MA et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008; 52: 539-50.
48. Groll AH, Mickiene D, Petraitiene R et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001; 45: 2845-55.
49. Clemons KV, Espiritu M, Parmar R et al. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006; 50: 1293-7.
50. Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007; 51: 3081-8.
51. Stevens DA, Ichinomiya M, Koshi Y et al. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for β-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 2006; 50: 3160-1.
52. Stevens DA, White TC, Perlin DS et al. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 2005; 51: 173-8.
53. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004; 48: 3407-11.
54. Wiederhold NP, Kontoyiannis DP, Prince RA et al. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 2005; 49: 5146-8.
55. Wiederhold NP. Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect. Curr Opin Infect Dis 2007; 20: 574-8.
56. Wiederhold NP. Paradoxical echinocandin activity: a limited in vitro phenomenon? Med Mycol 2009; 47 Suppl 1: S369-75.
57. Gardiner RE, Souteropoulos P, Park S et al. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med Mycol 2005; 43 Suppl 1: S299-305.
58. Munro CA, Selvaggini S, de Bruijn I et al. The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol Microbiol 2007; 63: 1399-413.
59. Wiederhold N, Wickes BL, Patterson T. Increased gene expression of mitogen-activated protein kinase A is associated with attenuated caspofungin activity in Aspergillus fumigatus. In: Abstracts of the Forty-sixth Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract M-364, p. 402. American Society for Microbiology, Washington, DC, USA.
60. Walker LA, Gow NA, Munro CA. Fungal echinocandin resistance. Fungal Genet Biol 2010; 47: 117-26.
61. Ramage G, Vandewalle K, Bachmann SP et al. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002; 46: 3634-6.
62. van Asbeck E, Clemons KV, Martinez M et al. Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis 2008; 62: 106-9.
63. Wiederhold N, Najvar LK, Bocanegra R et al. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 2007; 51: 1616-20.
64. Gumbo T, Drusano GL, Liu W et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006; 50: 3695-700.
65. Ostrosky-Zeichner L, Paetznick V, Rodriguez J et al. Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and serum (1,3)-β-D-glucan levels. Antimicrob Agents Chemother 2009; 53: 1639-41.
66. Petraitiene R, Petraitis V, Groll AH et al. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother 1999; 43: 2148-55.
67. Brzankalski GE, Najvar LK, Wiederhold NP et al. Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. J Antimicrob Chemother 2008; 62: 1094-100.
68. Warn PA, Sharp A, Morrissey G et al. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazoleresistant strain of Candida tropicalis. J Antimicrob Chemother 2005; 56: 590-3.
69. Ghannoum MA, Kim HG, Long L. Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis. J Antimicrob Chemother 2007; 59: 556-9.
70. Najvar LK, Bocanegra R, Wiederhold NP et al. Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice. Clin Microbiol Infect 2008; 14: 595-600.
71. Isham N, Ghannoum MA. Determination of MICs of aminocandin for Candida spp. and filamentous fungi. J Clin Microbiol 2006; 44: 4342-4.
72. Cocuaud C, Rodier MH, Daniault G et al. Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms. J Antimicrob Chemother 2005; 56: 507-12.
73. Kuhn DM, George T, Chandra J et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-80.
74. Shuford JA, Rouse MS, Piper KE et al. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J Infect Dis 2006; 194: 710-13.
75. Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother 2008; 62: 153-5.
76. Seidler M, Salvenmoser S, Muller FM. In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections. Int J Antimicrob Agents 2006; 28: 568-73.
77. Jacobson MJ, Piper KE, Nguyen G et al. In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother 2008; 52: 2242-3.
78. Choi HW, Shin JH, Jung SI et al. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob Agents Chemother 2007; 51: 1520-3.
79. Antachopoulos C, Meletiadis J, Sein T et al. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother 2007; 51: 881-7.
80. Bowman JC, Hicks PS, Kurtz MB et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001-12.
81. Kurtz MB, Heath IB, Marrinan J et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480-9.
82. Nakai T, Uno J, Ikeda F et al. In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 2003; 47: 1376-81.
83. Manavathu EK, Ramesh MS, Baskaran I et al. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004; 53: 386-9.
84. Clinical and Laboratory Standards Institute. Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi-Second Edition: Approved Standard M38-A2. CLSI, Wayne, PA, USA, 2008.
85. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-36.
86. Espinel-Ingroff A, Fothergill A, Ghannoum M et al. Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. J Clin Microbiol 2007; 45: 2180-2.
87. Odds FC, Motyl M, Andrade R et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 2004; 42: 3475-82.
88. Espinel-Ingroff A, Canton E, Peman J. Updates in antifungal susceptibility testing of filamentous fungi. Curr Fungal Infect Rep 2009; 3: 133-41.
89. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol 2009; 47: 3323-5.
90. Antachopoulos C, Meletiadis J, Sein T et al. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother 2008; 52: 321-8.
91. Ikawa K, Nomura K, Morikawa N et al. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections. J Antimicrob Chemother 2009; 64: 840-4.
92. Nicasio AM, Tessier PR, Nicolau DP et al. Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrob Agents Chemother 2009; 53: 1218-20.
93. Wiederhold NP, Kontoyiannis DP, Chi J et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464-71.
94. Lewis RE, Albert ND, Kontoyiannis DP. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother 2008; 61: 1140-4.
95. Warn P, Morrissey G, Morrissey J et al. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotercin B. J Antimicrob Chemother 2003; 51: 913-9.
96. Roberts J, Schock K, Marino S et al. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 3381-8.
97. Ibrahim AS, Bowman JC, Avanessian V et al. Caspofungin inhibits Rhizopus oryzae 1,3-β-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49: 721-7.
98. Spellberg B, Schwartz J, Fu Y et al. Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother 2006; 58: 973-9.
99. Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 2004; 126: 165-75.
100. Kontoyiannis DP, Lewis RE. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Updat 2003; 6: 257-69.
101. Johnson MD, MacDougall C, Ostrosky-Zeichner L et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48: 693-715.
102. Lewis R, Klepser ME, Pfaller MA. Combination systemic antifungal therapy for cryptococcosis, candidiasis, and aspergillosis. J Infect Dis Pharmacother 1999; 3: 61-83.
103. Graybill JR, Bocanegra R, Najvar LK et al. Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob Agents Chemother 2003; 47: 2373-5.
104. Roling EE, Klepser ME, Wasson A et al. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002; 43: 13-7.
105. Nagappan V, Boikov D, Vazquez JA. Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata. Antimicrob Agents Chemother 2010; 54: 522-5.
106. Marine M, Serena C, Pastor J et al. In vitro activity of micafungin combined with itraconazole against Candida spp. Int J Antimicrob Agents 2007; 30: 463-5.
107. Serena C, Marine M, Quindos G et al. In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp. Antimicrob Agents Chemother 2008; 52: 1529-32.
108. Heyn K, Tredup A, Salvenmoser S et al. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005; 49: 5157-9.
109. Lewis RE, Kontoyiannis DP. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. J Antimicrob Chemother 2005; 56: 887-92.
110. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-7.
111. Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326-32.
112. Perea S, Gonzalez G, Fothergill AW et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002; 46: 3039-41.
113. Philip A, Odabasi Z, Rodriguez J et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005; 49: 3572-4.
114. Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G et al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 2005; 49: 1232-5.
115. Dannaoui E, Lortholary O, Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother 2004; 48: 970-8.
116. O'Shaughnessy EM, Meletiadis J, Stergiopoulou T et al. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother 2006; 58: 1168-76.
117. Petraitis V, Petraitiene R, Hope WW et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentrationand dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009; 53: 2382-91.
118. Kirkpatrick WR, Perea S, Coco BJ et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564-8.
119. Luque JC, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 2003; 47: 1452-5.
120. Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: 1834-43.
121. Ratanatharathorn V, Flynn PM, van Burik JA et al. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients. In: Abstracts of the Forty-fourth Annual Meeting of the American Society of Hematology, Philadelphia, PA, 2002. Abstract M-719. American Society of Hematology, Washington, DC, USA.
122. Aliff TB, Maslak PG, Jurcic JG et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025-32.
123. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-9.
124. Hope WW, Drusano GL. Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin Microbiol Infect 2009; 15: 602-12.
125. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 2008; 47: 226-35.
126. Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006; 2: e35.
127. Lamaris GA, Lewis RE, Chamilos G et al. Caspofungin-mediated β-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008; 198: 186-92.
128. Chiller T, Farrokhshad K, Brummer E et al. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn Microbiol Infect Dis 2001; 39: 99-103.
129. Choi JH, Brummer E, Stevens DA. Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect 2004; 6: 383-9.
130. Buell D, Kovanda L, Drake T et al. Alternative day dosing of micafungin in the treatment of esophageal candidiasis. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract M-719, p. 419. American Society for Microbiology, Washington, DC, USA.
131. de Wet N, Llanos-Cuentas A, Suleiman J et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842-9.
132. Pettengell K, Mynhardt J, Kluyts T et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004; 20: 475-81.
133. Brown GWR, Turik M. Phase II, randomized, open label study of two intravenous dosing regimens of V-echinocandin in the treatment of esophageal candidiasis. In: Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2000. Abstract 1106, p. 371. American Society for Microbiology, Washington, DC, USA.
134. Betts RF, Nucci M, Talwar D et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-84.
135. Krause D, Reinhardt J, Vazquez J et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004; 48: 2021-4.
136. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24: 654-61.
137. Ota Y, Tatsuno K, Okugawa S et al. Relationship between the initial dose of micafungin and its efficacy in patients with candidemia. J Infect Chemother 2007; 13: 208-12.
138. Klont RR, Mennink-Kersten MA, Ruegebrink D et al. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis 2006; 43: e23-5.
139. Ota S, Tanaka J, Kahata K et al. Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study. Int J Hematol 2004; 79: 390-3.
140. Kohno S, Masaoka T, Yamaguchi H et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36: 372-9.